Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Respiratory

FDA Approves 20-Valent Pneumococcal Conjugate Vaccine Prevnar 20

Diana Ernst, RPh

June 11, 2021

The vaccine contains capsular polysaccharide conjugates for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease.

News, Sexually Transmitted Diseases

FDA Clears Point-of-Care Test for Chlamydia, Gonorrhea

Diana Ernst, RPh

April 6, 2021

The io instrument processes a single-use cartridge that contains all reagents for testing collected vaginal swabs and male urine samples.

COVID19

Pediatric Trial Evaluating Moderna’s COVID-19 Vaccine Begins

Diana Ernst, RPh

March 19, 2021

The phase 2/3 KidCOVE study [ClinicalTrials.gov: NCT04796896] is evaluating the safety and effectiveness of the vaccine in healthy children between 6 months and less than 12 years of age.

COVID19

Study Findings Do Not Support Use of Ivermectin for Mild COVID-19

Diana Ernst, RPh

March 15, 2021

The median time to resolution of COVID-19 symptoms was 10 days with ivermectin and 12 days with placebo.

COVID19

CDC Provides Guidance for Individuals Fully Vaccinated Against COVID-19

Diana Ernst, RPh

March 9, 2021

Fully vaccinated individuals can visit with other fully vaccinated people, or unvaccinated people from a single household who are at low risk for severe COVID-19 disease, indoors without wearing masks or physical distancing.

COVID19

Janssen Single-Shot COVID-19 Vaccine Gets Emergency Use Authorization

Diana Ernst, RPh

March 3, 2021

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.

COVID19

Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalization, Deaths

Diana Ernst, RPh

February 4, 2021

The combination therapy reduced the risk of hospitalization or death by 70%.

COVID19

ACIP Updates Recommendation on COVID-19 Vaccine Intervals

Diana Ernst, RPh

January 29, 2021

If keeping to the authorized schedule is not feasible, the second dose may be scheduled for administration up to 42 days (6 weeks) after the first dose, according to ACIP.